advanced pharmacology assignment

COURSE: ADVANCED PHARMACOLOGY ASSIGNMENT

  • (Please Avoid plagiarism and do not use any work from Course Heroes Professors checks both for plagiarism and Course heroes and their likes please) Capture every numbered question on the rubrics maintaining subtitles pls  Apa 7th edition,. Use 2 -4 articles from course resource and another 3 -4 articles from outside resource
  • Maintain title and sub titles according to the rubrics

Module 2: Cardiovascular and Respiratory Systems

 

Assignment Topic: Week 2: – Pharmacotherapy for Cardiovascular Disorders

 

……heart disease remains the No. 1 killer in America; nearly half of all Americans have high blood pressure, high cholesterol, or smoke—some of the leading risk factors for heart disease…

—Murphy et al., 2018

Despite the high mortality rates associated with cardiovascular disorders, improved treatment options do exist that can help address those risk factors that afflict the majority of the population today.  

As an advanced practice nurse, it is your responsibility to recommend appropriate treatment options for patients with cardiovascular disorders. To ensure the safety and effectiveness of drug therapy, advanced practice nurses must consider aspects that might influence pharmacokinetic and pharmacodynamic processes such as medical history, other drugs currently prescribed, and individual patient factors.

Reference: Murphy, S. L., Xu, J., Kochanek, K. D., & Arias, E. (2018). Mortality in the United States, 2017. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db328.htm

To Prepare
  • Review the Resources for this module and consider the impact of potential pharmacotherapeutics for cardiovascular disorders introduced in the media piece.
  • Review the case study assigned by your Instructor for this Assignment.
  • Select one the following factors: genetics, gender, ethnicity, age, or behavior factors.
  • Reflect on how the factor you selected might influence the patient’s pharmacokinetic and pharmacodynamic processes.
  • Consider how changes in the pharmacokinetic and pharmacodynamic processes might impact the patient’s recommended drug therapy.
  • Think about how you might improve the patient’s drug therapy plan based on the pharmacokinetic and pharmacodynamic changes. Reflect on whether you would modify the current drug treatment or provide an alternative treatment option for the patient.

(Please choose only one scenario out of the three scenarios below and write on it tnx)

CASE STUDY—-

Write a 2- to 3-page paper that addresses the following:

  • Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.
  • Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.
  • Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements.

 

CASE STUDY


This week you may again choose your own case from this list:

Case Study 1:
Patient AO has a history of obesity and has recently gained 9 pounds. The patient has been diagnosed with hypertension and hyperlipidemia. Drugs currently prescribed include the following:

Atenolol 12.5 mg daily
Doxazosin 8 mg daily
Hydralazine 10 mg qid
Sertraline 25 mg daily
Simvastatin 80 mg daily

Case Study 2:
Patient HM has a history of atrial fibrillation and a transient ischemic attack (TIA). The patient has been diagnosed with type 2 diabetes, hypertension, hyperlipidemia and ischemic heart disease. Drugs currently prescribed include the following:

Warfarin 5 mg daily MWF and 2.5 mg daily T, TH, Sat, Sun
Aspirin 81 mg daily
Metformin 1000 mg po bid
Glyburide 10 mg bid
Atenolol 100 mg po daily
Motrin 200 mg 1–3 tablets every 6 hours as needed for pain


Case Study 3:
Patient CB has a history of strokes. The patient has been diagnosed with type 2 diabetes, hypertension, and hyperlipidemia. Drugs currently prescribed include the following:

Glipizide 10 mg po daily
HCTZ 25 mg daily
Atenolol 25 mg po daily
Hydralazine 25 mg qid
Simvastatin 80 mg daily
Verapamil 180 mg CD daily Reference: ACC/ACHA


  Guideline on the Management of Blood Cholesterol
http://www.onlinejacc.org/content/accj/73/24/e285.full.pdf?_ga=2.211926493.853299748.1583090983-768093126.1583090983


Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
http://www.onlinejacc.org/content/accj/71/19/e127.full.pdf?_ga=2.119020992.853299748.1583090983-768093126.1583090983


Guideline on the Primary Prevention of Cardiovascular Disease
http://www.onlinejacc.org/content/accj/74/10/e177.full.pdf?_ga=2.120069185.853299748.1583090983-768093126.1583090983

Guideline for the Management of Patients With Atrial Fibrillation
http://www.onlinejacc.org/content/accj/74/1/104.full.pdf?_ga=2.181500014.853299748.1583090983-768093126.1583090983

Guideline for the Management of Heart Failure
http://www.onlinejacc.org/content/accj/70/6/776.full.pdf?_ga=2.182392302.853299748.1583090983-768093126.1583090983


Strategies to Enhance Application of Clinical Practice Guidelines in Patients With Cardiovascular Disease and Comorbid Conditions
http://www.onlinejacc.org/content/accj/64/17/1851.full.pdf?_ga=2.174568939.853299748.1583090983-768093126.1583090983

Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women
http://www.onlinejacc.org/content/accj/57/12/1404.full.pdf?_ga=2.214857950.853299748.1583090983-768093126.1583090983


Guideline for the Evaluation and Management of Patients With Syncope
http:/www.onlinejacc.org/content/accj/70/5/e39.full.pdf?_ga=2.186086496.853299748.1583090983-768093126.1583090983

Learning Resources

Required Readings

Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) St. Louis, MO: Elsevier.

  • Chapter 33, “Review of Hemodynamics” (pp. 285–289)
  • Chapter 37, “Diuretics” (pp. 290–296)
  • Chapter 38, “Drugs Acting on the Renin-Angiotensin-Aldosterone System” (pp. 297–307)
  • Chapter 39, “Calcium Channel Blockers” (pp. 308–312)
  • Chapter 40, “Vasodilators” (pp. 313–317)
  • Chapter 41, “Drugs for Hypertension” (pp. 316–324)
  • Chapter 42, “Drugs for Heart Failure” (pp. 325–336)
  • Chapter 43, “Antidysrhythmic Drugs” (pp. 337–348)
  • Chapter 44, “Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels” (pp. 349–363)
  • Chapter 45, “Drugs for Angina Pectoris” (pp. 364–371)
  • Chapter 46, “Anticoagulant and Antiplatelet Drugs” (pp. 372–388)

Required Media

Cardiovascular Disorders

Meet Dr. Norbert Myslinski as he discusses ACE inhibitors, angiotensin inhibitors, beta-blockers, calcium channel blockers, and diuretics as different categories of hypertension drugs. What potential drugs might be best recommended for patients suffering from hypertension? (8m)

Accessible player –Downloads–Download Video w/CCDownload AudioDownload Transcript

Walden University. (n.d.). Instructor feedback. https://mym.cdn.laureate-media.com/2dett4d/Walden/WWOW/1001/pulse_check/instructor_feedback/index.html#/

Rubric Detail

please pay attention to words in colors and highlight)

Select Grid View or List View to change the rubric’s layout.

Name: NURS_6521_Week2_Assignment_Rubric

 ExcellentGoodFairPoor
-Introduction must have a purpose statement   1-Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.23 (23%) – 25 (25%) The response accurately and completely explains in detail how the factor selected might influence the pharmacokinetic and pharmacodynamic processes in the patient.20 (20%) – 22 (22%) The response provides a basic explanation of how the factor selected might influence the pharmacokinetic and pharmacodynamic processes in the patient.18 (18%) – 19 (19%) The response inaccurately or vaguely explains how the factor selected might influence the pharmacokinetic and pharmacodynamic processes in the patient.0 (0%) – 17 (17%) The response inaccurately and vaguely explains how the factor selected might influence the pharmacokinetic and pharmacodynamic processes in the patient, or is missing.
2- Describe how changes in the processes might impact the patient’s recommended drug therapy. 2a-Be specific and 2b-provide examples.27 (27%) – 30 (30%) The response accurately and completely describes in detail how changes in the processes might impact the patient’s recommended drug therapy.

Accurate, complete, and aligned examples are provided to support the response.
24 (24%) – 26 (26%) The response accurately describes how changes in the processes might impact the patient’s recommended drug therapy.

Accurate examples may be provided to support the response.
21 (21%) – 23 (23%) The response inaccurately or vaguely describes how changes in the processes might impact the patient’s recommended drug therapy.

Inaccurate or vague examples are provided to support the response.
0 (0%) – 20 (20%) The response inaccurately and vaguely describes how changes in the processes might impact the patient’s recommended drug therapy, or is missing.

Inaccurate and vague examples may be provided to support the response, or is missing.
3-Explain how you might improve the patient’s drug therapy plan, and  3aexplain why you would make these recommended improvements.27 (27%) – 30 (30%) The response accurately and clearly explains in detail how to improve the patient’s drug therapy plan.

The response includes an accurate and detailed explanation to support the recommended improvements.
24 (24%) – 26 (26%) The response accurately explains how to improve the patient’s drug therapy plan.

The response may include an accurate explanation to support the recommended improvements.
21 (21%) – 23 (23%) The response inaccurately or vaguely explains how to improve the patient’s drug therapy plan.

The response may include an inaccurate, vague, or misaligned explanation to support the recommended improvements.
0 (0%) – 20 (20%) The response inaccurately and vaguely explains how to improve the patient’s drug therapy plan, or is missing.

The response may include an inaccurate and vague explanation to support the recommended improvements, or is missing.
Written Expression and Formatting – Paragraph Development and Organization:
Paragraphs make clear points that support well developed ideas, flow logically, and demonstrate continuity of ideas. Sentences are carefully focused–neither long and rambling nor short and lacking substance.
5 (5%) – 5 (5%) Paragraphs and sentences follow writing standards for flow, continuity, and clarity.4 (4%) – 4 (4%) Paragraphs and sentences follow writing standards for flow, continuity, and clarity 80% of the time.3.5 (3.5%) – 3.5 (3.5%) Paragraphs and sentences follow writing standards for flow, continuity, and clarity 60%–79% of the time.0 (0%) – 3 (3%) Paragraphs and sentences follow writing standards for flow, continuity, and clarity less than 60% of the time.
Written Expression and Formatting – English writing standards:
Correct grammar, mechanics, and proper punctuation
5 (5%) – 5 (5%) Uses correct grammar, spelling, and punctuation with no errors4 (4%) – 4 (4%) Contains a few (1–2) grammar, spelling, and punctuation errors3.5 (3.5%) – 3.5 (3.5%) Contains several (3–4) grammar, spelling, and punctuation errors0 (0%) – 3 (3%) Contains many (≥ 5) grammar, spelling, and punctuation errors that interfere with the reader’s understanding
Written Expression and Formatting – The paper follows correct APA format for title page, headings, font, spacing, margins, indentations, page numbers, running head, parenthetical/in-text citations, and reference list.5 (5%) – 5 (5%) Uses correct APA format with no errors4 (4%) – 4 (4%) Contains a few (1–2) APA format errors3.5 (3.5%) – 3.5 (3.5%) Contains several (3–4) APA format errors0 (0%) – 3 (3%) Contains many (≥ 5) APA format errors
Total Points: 100 

Name: NURS_6521_Week2_Assignment_Rubric